Affinage

SYT11

Synaptotagmin-11 · UniProt Q9BT88

Length
431 aa
Mass
48.3 kDa
Annotated
2026-06-10
61 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

Synaptotagmin-11 (Syt11) is a calcium-insensitive, transmembrane vesicular trafficking protein that resides on post-Golgi/endosomal and recycling vesicles distinct from synaptic vesicles, where it negatively regulates membrane internalization and modulates secretion across neurons, microglia, and astrocytes (PMID:30808661, PMID:28686317). In neurons Syt11 restrains synaptic vesicle endocytosis and spontaneous transmission through direct, Ca2+-independent interactions: its C2B domain binds and suppresses endophilin A1 to inhibit endocytosis and vesicle pool replenishment (PMID:37474308), while its C2A domain binds the non-canonical SNARE vti1a to suppress spontaneous excitatory release (PMID:34599505). Syt11 also scaffolds presynaptic signaling by recruiting the GABAB receptor subunit KCTD16 and Cav2.2 channels to post-Golgi vesicles and stabilizing them at the plasma membrane by limiting constitutive internalization, supporting GABAB-mediated presynaptic inhibition and long-term potentiation and memory (PMID:38698221, PMID:30808661). In microglia Syt11 inhibits activation, cytokine secretion, and phagocytosis of α-synuclein fibrils through binding vti1a/vti1b via its linker domain (PMID:28686317, PMID:37924268), and in astrocytes it stabilizes caveolae and restrains caveolae-mediated endocytosis through interactions with cavin1 and EHD2, conferring mechanoprotection (PMID:31908017). Syt11 is a short-lived protein degraded by the ubiquitin-proteasome system, and is the physiological substrate of the E3 ligase parkin; loss of parkin causes Syt11 accumulation that is mechanistically sufficient to impair dopamine release and drive late-onset dopaminergic neurodegeneration, identifying Syt11 as a key mediator of Parkinson's disease-like neurotoxicity (PMID:29311685, PMID:39901263, PMID:32976921). Palmitoylation at Cys39/Cys40 stabilizes Syt11 against endolysosomal degradation and promotes α-synuclein binding to membranes, shifting α-synuclein toward its aggregation-prone monomeric form (PMID:36787382). Beyond the nervous system, Syt11 acts as a trafficking and scaffolding factor in cancer, binding the MKK7–JNK1 module to promote EMT-related gene expression in gastric cancer (PMID:35768842) and cooperating with Impad1 to control Golgi morphology and the invasive secretome (PMID:36170810).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 2005 Medium

    Established that Syt11 transcription is epigenetically and cis-regulated, the first mechanistic handle on how its levels are set before any functional role was known.

    Evidence EMSA and reporter assays with methylated and polymorphic promoter constructs

    PMID:15777718 PMID:17192956

    Open questions at the time
    • Does not connect promoter regulation to a specific cellular function
    • Disease association is correlative
  2. 2012 Medium

    Resolved where Syt11 acts in neurons, showing it is targeted to presynaptic vesicles and plasma membrane and recruited by neuroligins, placing it at synaptic membranes rather than postsynaptic sites.

    Evidence Immunogold EM, neuroligin co-culture, and fractionation in rat hippocampal neurons

    PMID:22960622

    Open questions at the time
    • Functional consequence of synaptic localization not established
    • Molecular partners mediating vesicle targeting unknown
  3. 2014 Medium

    Provided the first domain-level interaction map, distinguishing C2A (vti1a) from C2B (SND1, Ago2, FMRP) binding and linking Syt11 to RISC components in β-cells.

    Evidence Co-IP, pull-down, and domain-deletion constructs in pancreatic β-cells

    PMID:24882364

    Open questions at the time
    • Functional role of RISC association not demonstrated
    • Single-cell-type, single-study evidence
  4. 2016 High

    Connected Syt11 to lysosomal/autophagic homeostasis by showing ATP13A2 loss lowers Syt11 transcriptionally (via mTORC1/TFEB) and post-translationally, with reduced Syt11 itself causing lysosomal dysfunction.

    Evidence Knockdown, epistasis, transcriptional reporters, ubiquitination and lysosomal assays

    PMID:27278822

    Open questions at the time
    • Direct molecular mechanism by which Syt11 supports lysosomal function not defined
    • Link to dopaminergic neuron survival not tested here
  5. 2017 High

    Defined an immune-regulatory function, showing Syt11 suppresses microglial cytokine secretion and phagocytosis and restrains NF-κB, broadening its role beyond neurons.

    Evidence shRNA knockdown with rescue, ELISA, NF-κB reporter, phagocytosis and localization assays in primary microglia

    PMID:28686317

    Open questions at the time
    • Direct binding partner mediating cytokine suppression not yet identified at this stage
    • In vivo relevance not tested
  6. 2018 High

    Identified Syt11 as a physiological parkin substrate and showed its accumulation impairs dopamine release and drives dopaminergic degeneration, providing a mechanistic basis for parkin-linked Parkinson's disease.

    Evidence Viral overexpression, knockout mice, dopamine measurements, EM, and genetic rescue in vivo

    PMID:29311685

    Open questions at the time
    • Endocytic effector mediating the dopamine-release defect not yet identified here
    • Whether endogenous accumulation alone is sufficient not resolved at this stage
  7. 2019 High

    Characterized Syt11's vesicle identity and core neuronal phenotype, placing it on activity-recycling trafficking endosomes whose loss impairs LTP and memory while sparing fast transmitter release.

    Evidence Constitutive and conditional knockout mice, live imaging, electrophysiology, behavior, fractionation

    PMID:30808661

    Open questions at the time
    • Molecular mechanism of slow desynchronized exocytosis unresolved
    • Effectors linking the vesicle pool to LTP not defined here
  8. 2019 Medium

    Extended Syt11's endocytic-control function to astrocytes, identifying cavin1 and EHD2 as direct partners through which it stabilizes caveolae and provides mechanoprotection.

    Evidence Knockout astrocytes, EM, live imaging, Co-IP, endocytosis and hypoosmotic stimulation assays

    PMID:31908017

    Open questions at the time
    • Structural basis of cavin1/EHD2 binding not mapped
    • Single-lab evidence
  9. 2020 Medium

    Quantified Syt11 turnover, establishing it as a short-lived proteasome substrate whose degradation is activity- and parkin-dependent in neurons but parkin-independent in astrocytes.

    Evidence Cycloheximide chase, MG132, activity stimulation, parkin manipulation across neurons and astrocytes

    PMID:32976921

    Open questions at the time
    • The non-parkin E3 ligase in astrocytes not identified here
    • Single-lab study
  10. 2021 High

    Pinpointed the molecular target for Syt11's suppression of spontaneous release, mapping a high-affinity C2A–vti1a interaction whose disruption reverses the knockout phenotype.

    Evidence KO and overexpression in hippocampal neurons, mEPSC recording, GST pull-down, Co-IP, domain mapping, vti1a knockdown rescue

    PMID:34599505

    Open questions at the time
    • How vti1a binding mechanically suppresses fusion not resolved
    • Relationship to the endosomal vesicle pool not integrated
  11. 2022 Medium

    Revealed non-neural functions of Syt11 as a signaling scaffold (MKK7–JNK1) driving EMT in gastric cancer and as an Impad1 partner controlling Golgi morphology and the invasive secretome.

    Evidence Phospho-kinase array, Co-IP, shRNA, xenograft and metastasis assays; interaction and secretome studies in lung cancer

    PMID:35768842 PMID:36170810

    Open questions at the time
    • Whether scaffolding and trafficking roles are mechanistically linked unclear
    • Single-lab evidence for each context
  12. 2022 Medium

    Showed Syt11 localizes to insulin granules and suppresses insulin secretion upstream of exocytosis, extending its secretion-braking role to pancreatic β-cells.

    Evidence siRNA knockdown, insulin ELISA, patch-clamp, confocal co-localization in INS-1 cells

    PMID:35753051

    Open questions at the time
    • Molecular effector in β-cells not identified
    • Single-lab, single-study
  13. 2023 High

    Identified endophilin A1 as the C2B effector through which Syt11 inhibits synaptic vesicle endocytosis, directly linking its trafficking role to the dopamine-release defect seen with accumulation.

    Evidence KO mice, calyx of Held electrophysiology, Co-IP, peptide competition in vitro and in vivo, EndoA1 knockdown rescue

    PMID:37474308

    Open questions at the time
    • Structural model of the C2B–EndoA1 interface not defined
    • How endocytic braking integrates with vti1a-dependent fusion control unresolved
  14. 2023 High

    Established a post-translational switch—palmitoylation at Cys39/Cys40—that stabilizes Syt11 and links it to pathological α-synuclein membrane binding and aggregation.

    Evidence Acyl-RAC, site-directed mutagenesis, fractionation, pulse-chase, α-synuclein biochemistry in mouse and human brain

    PMID:36787382

    Open questions at the time
    • Palmitoyltransferase responsible not identified
    • Causal contribution to in vivo neurodegeneration not directly tested here
  15. 2023 High

    Confirmed in vivo the microglial immune-suppressive role and mapped its linker-domain binding to vti1a/vti1b, with a competitive peptide phenocopying knockdown.

    Evidence Inducible microglia-specific cKO, LPS and α-synuclein fibril models, Co-IP, competitive peptide inhibition

    PMID:37924268

    Open questions at the time
    • How vti1a/vti1b binding restrains conventional cytokine secretion mechanistically unclear
    • Interplay with neuronal Syt11 loss in PD not addressed
  16. 2024 High

    Defined Syt11 as a scaffold assembling presynaptic GABAB receptor/Cav2.2 signaling complexes and stabilizing them at the membrane, providing a mechanism for its support of presynaptic inhibition.

    Evidence Reciprocal Co-IP, co-localization, KO neurons, electrophysiology, internalization assays

    PMID:38698221

    Open questions at the time
    • Binding interfaces for KCTD16 and Cav2.2 not mapped
    • Relationship between scaffolding and endocytic-braking functions unresolved
  17. 2024 Medium

    Demonstrated a developmental-window-specific role, where adolescent dopamine-neuron Syt11 loss produces persistent dopamine over-transmission and schizophrenia-like behavior reversible by D2R-targeted drugs.

    Evidence Temporally controlled dopamine-neuron conditional KO, behavior, dopamine measurements, pharmacological rescue

    PMID:39632880

    Open questions at the time
    • Molecular basis of the adolescent-specific requirement unknown
    • Single-lab study
  18. 2025 Medium

    Established Syt11 accumulation as mechanistically sufficient for parkin-associated PD and explained why parkin KO is phenotypically mild via compensatory Syt11 upregulation.

    Evidence Parkin KO and adult viral KD comparison, Syt11 overexpression sufficiency tests, dopamine and behavioral readouts

    PMID:39901263

    Open questions at the time
    • Mechanism of developmental Syt11 compensation not defined
    • Single-lab study
  19. 2025 Medium

    Identified VHL as a second E3 ligase that directly binds and proteasomally degrades Syt11, downregulating SPINK1 and suppressing gastric cancer growth, broadening Syt11's degradation control beyond parkin.

    Evidence Co-IP, cycloheximide chase, MG132, ubiquitination assay, transcriptomics, invasion/growth assays

    PMID:40576306

    Open questions at the time
    • Whether VHL regulates Syt11 in neurons not tested
    • Single-lab study

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unknown how Syt11's distinct domain-specific effector interactions (C2A–vti1a, C2B–EndoA1, linker–vti1a/vti1b, scaffolding of KCTD16/Cav2.2) are coordinated on a single vesicle population and how this integration is tuned across neurons, glia, and peripheral cells.
  • No structural model integrating the multiple binding surfaces
  • No single study reconciles fusion-suppression and endocytosis-braking roles
  • Cell-type-specific effector usage not systematically compared

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 4 GO:0098772 molecular function regulator activity 3 GO:0008289 lipid binding 1
Localization
GO:0005886 plasma membrane 3 GO:0031410 cytoplasmic vesicle 3 GO:0005768 endosome 2 GO:0005794 Golgi apparatus 2
Pathway
R-HSA-5653656 Vesicle-mediated transport 4 R-HSA-112316 Neuronal System 3 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 2
Partners
CACNA2/CAV2.2CAVIN1EHD2KCTD16PARK2/PARKINSH3GL2VTI1AVTI1B

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2016 ATP13A2 depletion negatively regulates SYT11 at both transcriptional and post-translational levels: decreased SYT11 transcription is controlled by MYCBP2-induced ubiquitination of TSC2, leading to mTORC1 activation and decreased TFEB-mediated transcription of SYT11, while increased protein turnover is regulated by SYT11 ubiquitination and degradation. Decreased SYT11 levels in turn induce lysosomal dysfunction and impaired degradation of autophagosomes. Genetic knockdown, epistasis analysis, transcriptional reporter assays, ubiquitination assays, lysosomal function assays Nature communications High 27278822
2018 Synaptotagmin-11 is a physiological substrate of parkin (E3 ubiquitin ligase). Parkin deficiency leads to synaptotagmin-11 accumulation. Unilateral overexpression of full-length (but not C2B-truncated) synaptotagmin-11 in the substantia nigra pars compacta impairs striatal dopamine release by inhibiting endocytosis and vesicle pool replenishment, causing late-onset dopaminergic neuron degeneration and progressive motor abnormalities. SYT11 knockdown or knockout in dopaminergic neurons reversed parkin-deficiency-induced PD-like neurotoxicity. In vivo overexpression (viral vector), knockout mice, dopamine release measurements, electron microscopy, genetic rescue experiments Nature communications High 29311685
2019 In neurons, Syt11 resides on abundant vesicles resembling trafficking endosomes (distinct from synaptic vesicles) that recycle via the plasma membrane in an activity-dependent manner with slow, desynchronized exocytosis. Constitutive Syt11 knockout mice die shortly after birth. Conditional knockout of Syt11 in excitatory forebrain neurons impairs long-term synaptic potentiation and memory without affecting fast neurotransmitter or peptide secretion. Conditional and constitutive knockout mice, live-cell imaging, electrophysiology, memory behavioral assays, vesicle fractionation Genes & development High 30808661
2017 Syt11 inhibits cytokine secretion and phagocytosis in microglia. Syt11 knockdown increases IL-6, TNF-α, IL-1β, and iNOS synthesis and activates NF-κB. Syt11 specifically regulates conventional secretion of IL-6 and TNF-α. Syt11 localizes to the trans-Golgi network and recycling endosomes and is recruited to phagosomes. Syt11 deficiency enhances phagocytosis including that of α-synuclein fibrils. All KD phenotypes were rescued by shRNA-resistant Syt11. shRNA knockdown in primary microglia, overexpression rescue, ELISA, NF-κB reporter, immunofluorescence/confocal microscopy, phagocytosis assay Glia High 28686317
2021 Syt11 suppresses spontaneous (miniature) excitatory neurotransmission. Syt11-KO hippocampal neurons show increased mEPSC frequency; Syt11 overexpression decreases mEPSC frequency without affecting amplitude, indicating presynaptic regulation. Syt11 directly interacts with the non-canonical SNARE protein vti1a (C2A domain of Syt11 binds vti1a with high affinity), and vti1a knockdown reverses the Syt11-KO phenotype, identifying vti1a as the primary target. Knockout and overexpression in hippocampal neurons, electrophysiology (mEPSC recording), GST pull-down, co-immunoprecipitation, affinity purification, domain deletion analysis Journal of neurochemistry High 34599505
2023 Syt11 is palmitoylated at Cys39 and Cys40 (adjacent to its transmembrane domain) in mouse and human brain tissue and cultured neurons. Palmitoylation localizes Syt11 to digitonin-insoluble intracellular membranes and protects it from endolysosomal degradation. Palmitoylated Syt11 increases its own abundance and enhances α-synuclein binding to intracellular membranes, decreasing the physiologic tetrameric form and increasing the aggregation-prone monomeric form. A palmitoylation-deficient mutant failed to replicate these effects. Acyl-resin assisted capture (acyl-RAC), site-directed mutagenesis, subcellular fractionation (digitonin), pulse-chase protein stability assays, α-synuclein biochemical fractionation, neuronal overexpression Science signaling High 36787382
2023 Syt11 directly binds endophilin A1 (EndoA1) via a Ca2+-independent interaction (Syt11 C2B domain, aa 314-336 with EndoA1 N-terminus) and inhibits synaptic vesicle endocytosis through EndoA1. Syt11 KO accelerates SV endocytosis and causes abnormal membrane partitioning of synaptic proteins. EndoA1 knockdown reverses the Syt11-KO phenotype. A peptide from Syt11 C2B blocked the interaction in vitro and in vivo and inhibited SV endocytosis at the calyx of Held. Knockout mice, electrophysiology (capacitance, calyx of Held), Co-IP, in vitro peptide competition assays, EndoA1 knockdown rescue, live imaging The Journal of neuroscience High 37474308
2024 Syt11 binds both the auxiliary GABAB receptor subunit KCTD16 and Cav2.2 Ca2+ channels, recruiting them to post-Golgi vesicles to facilitate assembly of GBR/Cav2.2 signaling complexes. Syt11 also stabilizes GBRs and Cav2.2 at the neuronal plasma membrane by inhibiting constitutive internalization. Syt11 KO neurons show deficits in presynaptic GBRs and Cav2.2 channels, reduced neurotransmitter release, and decreased GBR-mediated presynaptic inhibition. Co-immunoprecipitation, co-localization (confocal), knockout mouse neurons, electrophysiology (neurotransmitter release, presynaptic inhibition), internalization assays EMBO reports High 38698221
2023 In microglia in vivo, Syt11 inhibits microglial activation, cytokine secretion (IL-6, TNF-α, IL-1β, iNOS), and phagocytosis of α-synuclein fibrils. Syt11 directly binds vti1a and vti1b via its linker domain. A competitive peptide from the Syt11 linker domain inhibited vti1a/vti1b interaction in vitro and in cells and induced cytokine hypersecretion in WT microglia upon LPS treatment, phenocopying Syt11 knockdown. Inducible microglia-specific conditional knockout (cKO) mice, LPS inflammation model, α-synuclein fibril injection model, Co-IP/pull-down, competitive peptide inhibition, cytokine mRNA and protein measurement Journal of neurochemistry High 37924268
2022 SYT11 functions as a scaffold protein, binding both MKK7 and JNK1 to promote JNK1 phosphorylation, leading to cJun activation and downstream EMT-related gene expression (ANGPTL2, THBS4, Vimentin, JAM3) in gastric cancer. SYT11 shRNA reduced spheroid formation, tumor growth, and liver metastasis; SYT11-ASO showed antitumor activity in xenograft models. Phospho-kinase array, co-immunoprecipitation, western blot, shRNA knockdown, xenograft mouse model, liver metastasis assay Journal of experimental & clinical cancer research Medium 35768842
2022 Impad1 modulates Golgi apparatus morphology and vesicular trafficking through its interaction with Syt11. Inhibiting either Impad1 or Syt11 disrupts the cancer cell secretome and extracellular matrix composition, reversing the invasive/metastatic phenotype of lung cancer cells. High-throughput in vitro/in vivo screens, co-immunoprecipitation/interaction studies, Golgi morphology imaging, secretome analysis, invasion/metastasis assays Cell reports Medium 36170810
2019 Syt11 stabilizes caveolar structures on the astrocyte cell surface and regulates caveolae-mediated endocytosis and caveolar responses to mechanical (hypoosmotic) stimuli. Syt11 KO accelerated caveolae-mediated endocytosis and markedly reduced caveolar structures on the cell surface. Syt11 directly interacts with cavin1 and EHD2 (but not caveolin-1) and regulates their turnover, providing a mechanoprotective role. Knockout astrocytes, live imaging, electron microscopy, Co-IP/pull-down, endocytosis assays, hypoosmotic stimulation, proteasome inhibitor experiments FASEB journal Medium 31908017
2014 Synaptotagmin-11 interacts with components of the RNA-induced silencing complex (RISC) in pancreatic β-cells: the C2A domain interacts with the Q-SNARE Vti1a, while the C2B domain interacts with SND1, Ago2, and FMRP. Binding to SND1 was direct, via SND1's N-terminal tandem repeats. Co-immunoprecipitation, pull-down, domain deletion constructs (C2A, C2B), MS identification of binding partners FEBS letters Medium 24882364
2024 Syt11 deficiency specifically in dopamine neurons during early adolescence (but not in adults) leads to persistent dopamine over-transmission and schizophrenia-like behaviors (social deficits, etc.) in mice. D2R-targeting interventions (presynaptic or postsynaptic) in the mPFC showed acute and long-lasting therapeutic effects on social deficits. Conditional knockout (dopamine neuron-specific, adolescent vs. adult), behavioral assays, dopamine transmission measurements, pharmacological rescue with D2R drugs Nature communications Medium 39632880
2020 Syt11 is a short-lived protein (half-life ~1.49 h in neurons) primarily degraded by the ubiquitin-proteasome pathway (UPP). Degradation is accelerated under sustained neuronal activity in a parkin-dependent manner. In astrocytes, Syt11 has a faster turnover (half-life ~0.58 h), partially UPP-dependent, but parkin-independent even under hypoosmotic mechanical stress. Cycloheximide chase assay, proteasome inhibitor (MG132), neuronal activity stimulation, parkin overexpression/knockdown, half-life measurements in neurons and astrocytes Neuroscience letters Medium 32976921
2007 The number of 33-bp repeats in the Syt11 promoter region, which contain an Sp1 binding site, affects Syt11 transcriptional activity. A SNP in the Syt11 5'UTR region, where YY1 can bind, also affects Syt11 transcriptional activity. Transcriptional reporter (luciferase) assays, gel mobility shift assays (EMSA), polymorphism analysis in schizophrenia patients American journal of medical genetics. Part B Medium 17192956
2005 Non-CpG methylation in the Syt11 promoter reduces transcriptional activity: methylated cytosines in the coding (minus) strand of the promoter reduce Sp family protein binding (demonstrated by gel mobility shift assay) and decrease reporter gene expression. Gel mobility shift assay (EMSA), artificially methylated promoter constructs, transient transcription reporter assays Gene Medium 15777718
2012 Syt11 in rat hippocampal neurons is targeted to both dendrite and axon compartments and forms higher molecular weight complexes via its transmembrane domain. Immunogold electron microscopy showed Syt11 predominantly in presynaptic neurotransmitter vesicles and plasma membrane, with rare postsynaptic localization. Both neuroligin-1 and neuroligin-2 recruit Syt11 in neuron co-culture, associating it with excitatory and inhibitory presynapses respectively. Immunocytochemistry, immunogold electron microscopy, co-culture with neuroligins, SDS-PAGE (higher MW complex detection), subcellular fractionation Neuroscience Medium 22960622
2022 In pancreatic β-cells (INS-1 832/13), Syt11 co-localizes with insulin, indicating localization in insulin granules. Knockdown of Syt11 resulted in increased basal and glucose-induced insulin secretion without changes in exocytosis or voltage-gated Ca2+ currents, suggesting a role in suppressing insulin release upstream of final exocytotic steps. siRNA knockdown, ELISA (insulin secretion), patch-clamp electrophysiology, confocal microscopy co-localization Acta physiologica Medium 35753051
2025 VHL (an E3 ubiquitin ligase) physically binds SYT11 and promotes its proteasome-dependent degradation without affecting SYT11 mRNA. VHL overexpression decreases SYT11 protein half-life; MG132 (proteasome inhibitor) reverses SYT11 degradation by VHL. VHL knockdown reduces SYT11 ubiquitination. VHL-mediated SYT11 degradation leads to downregulation of SPINK1 and suppression of gastric cancer cell growth and invasion. Immunoprecipitation, overexpression/knockdown, cycloheximide chase, MG132 proteasome inhibitor, transcriptome sequencing, invasion/growth assays Journal of cellular and molecular medicine Medium 40576306
2025 Compensatory upregulation of Syt11 in parkin knockout mice conceals PD-associated phenotypes: Syt11 is upregulated in parkin KO mice during suckling stage and in adult parkin knockdown (KD) mice. Parkin KD in adult SNpc impairs dopamine release and causes motor deficits (unlike parkin KO). Syt11 overexpression alone induces PD-like motor and non-motor impairments and impairs dopamine release and reuptake, establishing Syt11 accumulation as mechanistically sufficient for parkin-associated PD pathogenesis. Parkin KO and KD mouse models (viral vector KD in adult SNpc), dopamine release measurements, behavioral assays, Syt11 overexpression, western blot Cell communication and signaling Medium 39901263

Source papers

Stage 0 corpus · 61 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nature communications 159 27278822
2011 Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC medical genetics 137 21812969
1994 Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1. DNA research : an international journal for rapid publication of reports on genes and genomes 122 7584044
2021 Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease. Acta pharmaceutica Sinica. B 117 34729301
2012 Reduced insulin secretion correlates with decreased expression of exocytotic genes in pancreatic islets from patients with type 2 diabetes. Molecular and cellular endocrinology 107 22939844
2018 Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology. Nature communications 88 29311685
2009 Differential mRNA expression patterns of the synaptotagmin gene family in the rodent brain. The Journal of comparative neurology 70 19030179
2019 Synaptotagmin-11 mediates a vesicle trafficking pathway that is essential for development and synaptic plasticity. Genes & development 59 30808661
2014 Mammalian Non-CpG Methylation: Stem Cells and Beyond. Biology 56 25393317
2008 A comparison of molecular alterations in environmental and genetic rat models of ADHD: a pilot study. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 54 18937310
2017 The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal. Neuroscience letters 50 28830825
2021 Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations. Brain : a journal of neurology 48 33349842
2017 Molecular Mechanisms for the Coupling of Endocytosis to Exocytosis in Neurons. Frontiers in molecular neuroscience 35 28348516
2017 Synaptotagmin-11 inhibits cytokine secretion and phagocytosis in microglia. Glia 35 28686317
2011 Genetics of Parkinson's disease and essential tremor. Current opinion in neurology 35 21734494
2007 Synaptotagmin XI as a candidate gene for susceptibility to schizophrenia. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 34 17192956
2016 Genome-wide assessment of Parkinson's disease in a Southern Spanish population. Neurobiology of aging 33 27393345
2023 Palmitoylation of the Parkinson's disease-associated protein synaptotagmin-11 links its turnover to α-synuclein homeostasis. Science signaling 31 36787382
2005 Effects of methylation of non-CpG sequence in the promoter region on the expression of human synaptotagmin XI (syt11). Gene 30 15777718
2020 Schizophrenia-associated MicroRNA-Gene Interactions in the Dorsolateral Prefrontal Cortex. Genomics, proteomics & bioinformatics 27 32006661
2017 MiR-335 overexpression impairs insulin secretion through defective priming of insulin vesicles. Physiological reports 27 29122960
2023 Novel Drug Targets for Atrial Fibrillation Identified Through Mendelian Randomization Analysis of the Blood Proteome. Cardiovascular drugs and therapy 25 37212950
2018 Detergent Insoluble Proteins and Inclusion Body-Like Structures Immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the Amygdala of Cognitively Impaired Elderly Persons. Journal of neuropathology and experimental neurology 22 29186589
2018 Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A. Cancer genomics & proteomics 21 30194076
2014 Synaptotagmin 11 interacts with components of the RNA-induced silencing complex RISC in clonal pancreatic β-cells. FEBS letters 20 24882364
2010 Developmental expression of Synaptotagmin isoforms in single calyx of Held-generating neurons. Molecular and cellular neurosciences 19 20470891
2022 Synaptotagmin 11 scaffolds MKK7-JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis. Journal of experimental & clinical cancer research : CR 18 35768842
2021 Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models. Genome medicine 18 34702310
2022 The highly expressed calcium-insensitive synaptotagmin-11 and synaptotagmin-13 modulate insulin secretion. Acta physiologica (Oxford, England) 14 35753051
2024 Synaptotagmin-11 deficiency mediates schizophrenia-like behaviors in mice via dopamine over-transmission. Nature communications 12 39632880
2019 Link synthetic lethality to drug sensitivity of cancer cells. Briefings in bioinformatics 12 29300844
2013 Meta-analysis supports association of a functional SNP (rs1801133) in the MTHFR gene with Parkinson's disease. Gene 12 23916622
2022 miR-146a/KLF4 axis in epileptic mice: A novel regulator of synaptic plasticity involving STAT3 signaling. Brain research 11 35728661
2021 Synaptotagmin-11 inhibits spontaneous neurotransmission through vti1a. Journal of neurochemistry 11 34599505
2023 Tumor-associated macrophages respond to chemotherapy by detrimental transcriptional reprogramming and suppressing stabilin-1 mediated clearance of EGF. Frontiers in immunology 10 36960065
2022 Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis. Cell reports 10 36170810
2019 Synaptotagmin-11 regulates the functions of caveolae and responds to mechanical stimuli in astrocytes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 10 31908017
2012 Developmental expression and subcellular distribution of synaptotagmin 11 in rat hippocampus. Neuroscience 9 22960622
2014 Association analysis of STK39, MCCC1/LAMP3 and sporadic PD in the Chinese Han population. Neuroscience letters 8 24631562
2024 Synaptotagmin-11 facilitates assembly of a presynaptic signaling complex in post-Golgi cargo vesicles. EMBO reports 6 38698221
2023 Synaptotagmin-11 Inhibits Synaptic Vesicle Endocytosis via Endophilin A1. The Journal of neuroscience : the official journal of the Society for Neuroscience 6 37474308
2022 Distribution of Copy Number Variation in SYT11 Gene and Its Association with Growth Conformation Traits in Chinese Cattle. Biology 6 35205089
2023 Synaptotagmin-11 regulates immune functions of microglia in vivo. Journal of neurochemistry 5 37924268
2025 Comprehensive characterization of the RNA editing landscape in the human aging brains with Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association 4 40631452
2020 Parkin-dependent and -independent degradation of synaptotagmin-11 in neurons and astrocytes. Neuroscience letters 4 32976921
2025 In vitro and in vivo antidiabetic evaluation of new Coumarin and Chromone derivatives: Design, synthesis and molecular modeling. Bioorganic chemistry 3 40101577
2025 Plasma proteins and onset of atherosclerosis: integrating human plasma proteogenomics, transcriptomics and in vivo evidence. Journal of translational medicine 3 41254737
2024 Synaptotagmins family affect glucose transport in retinal pigment epithelial cells through their ubiquitination-mediated degradation and glucose transporter-1 regulation. World journal of diabetes 3 38766439
2023 From Diagnosis to Treatment: A Comprehensive Review of Biomarkers and Therapeutic Advances in Parkinson's Disease. Annals of neurosciences 3 40017568
2025 Compensatory synaptotagmin-11 expression conceals parkinson's disease-like phenotypes in parkin knockout mice. Cell communication and signaling : CCS 2 39901263
2025 Inflammatory Gene Signature Identified by Machine Algorithms Reveals Novel Biomarkers of Coronary Artery Disease. Journal of inflammation research 2 39959641
2025 VHL-Mediated SYT11 Degradation Suppresses Gastric Cancer Cell Growth and Invasion Through Downregulation of SPINK1. Journal of cellular and molecular medicine 1 40576306
2025 To reveal biomarkers related to macrophage and lactic acid metabolism in renal fibrosis and explore their mechanisms. Frontiers in immunology 1 40755781
2024 Role of SYT11 in human pan-cancer using comprehensive approaches. European journal of medical research 1 38890718
2020 The rs3129882/rs4248166 in HLA-DRA and rs34372695 in SYT11 are not associated with sporadic Parkinson's disease in Central Chinese population. The International journal of neuroscience 1 32253955
2026 The genetic architecture of Parkinson's disease in Mexico: a systematic review. Frontiers in aging neuroscience 0 41798285
2025 Ca2+-Affinitive and Non-Ca2+-Affinitive Synaptotagmins in Human Pan-cancer. Neuromolecular medicine 0 40676322
2025 Protein regulatory network mediated by palmitoylation modifications in the pathological progression of Parkinson's disease: a narrative review. Frontiers in immunology 0 40703511
2025 Identification of breast cancer susceptibility genes via trans-ethnic Mendelian randomization and colocalization analyses. Medicine 0 41367007
2024 Use of mendelian randomization to assess the causal associations of circulating plasma proteins with 12-lead ECG parameters. International immunopharmacology 0 39486179
2021 De Novo 1q21.3q22 Duplication Revaluation in a "Cold" Complex Neuropsychiatric Case with Syndromic Intellectual Disability. Genes 0 33807234

Missed literature

Know a paper Affinage missed for SYT11? Flag it for the maintainers and the community.

No submissions yet.